导管切除和口服抗凝药用于心房的二次中风预防:STABLED随机临床试验
Kazumi Kimura1,2, Yasuhiro Nishiyama1,3, Yu-Ki Iwasaki4
1Department of Neurology, Nippon Medical School, Tokyo, Japan.
JAMA neurology
|March 2, 2026
概括
在标准治疗中添加导管切除并没有显著降低最近中风的心房动患者中风或复合事件风险. 这项研究不足以检测出有意义的差异.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 医疗干预 医疗干预
背景情况:
- 患有心房动 (AF) 和最近中风的患者面临高复发风险.
- 导管切除假设可以减轻AF患者中风,心力衰竭和死亡率的风险.
研究的目的:
- 评估导管切除与标准治疗相结合的疗效和安全性,以减少近期中风的AF患者中复发性中风或复合性结局.
- 该STABLED试验的目的是提供有关此干预的关键数据.
主要方法:
- 一个开放的,随机的临床试验 (STABLED) 涉及249名非膜AF和最近缺血性中风的患者.
- 参与者接受了标准疗法或标准疗法加导管切除4周后的edoxaban.
- 主要终点是复发性缺血性中风,全身血栓塞,全因死亡和心力衰竭住院治疗的组合.
主要成果:
- 导管切除加上标准治疗 (4.9%对5.6%每人-年) 没有观察到初级复合终点的显著降低.
- 标准治疗和导管切除组的死亡率分别为每100人/年1.0和2.8.
- 发生了两个与切除相关的不良事件 (心脏吸管,中风) (每一个为0.8%).
结论:
- 在标准治疗中添加导管切除并没有显著降低最近中风的AF患者的初级复合终点.
- 该研究表明,由于事件发生率低于预期,它可能无法检测出临床上显著的差异.
相关概念视频
Venous Thrombosis III: Interprofessional Care
426
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
426
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Acute Coronary Syndrome IV: Interprofessional Care
349
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
349
Cardiac Catheterization II: Right Heart Catheterization
1.4K
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
1.4K
Dysrhythmias VI: Management of Dysrhythmias
547
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
547


